<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124347">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01867073</url>
  </required_header>
  <id_info>
    <org_study_id>PG01/04/11</org_study_id>
    <nct_id>NCT01867073</nct_id>
  </id_info>
  <brief_title>A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <authority>Singapore: Domain Specific Review Boards</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical
      Company, Ltd, and is currently undergoing clinical investigation at the National University
      Health System (NUHS), Singapore. The proposed correlative pharmacodynamic and
      pharmacogenetic biomarker study is initiated and funded by the investigators, and will be
      conducted in conjunction with the extension phase I protocol of OPB-51602 in patients with
      advanced solid tumours (Study code 266-09-801-01/ DSRB protocol B/09/514). All biomarker and
      pharmacogenetic samples will be collected, stored and analysed at the local laboratory of
      the study site (Cancer Science Institute, National University Health System, Singapore, Dr
      Boon-Cher Goh).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Inhibition of STAT3 phosphorylation in peripheral mononuclear blood cells (PBMCs)pharmacodynamic effect of OPB-51602 in surrogate tissue.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To identify single nucleotide polymorphisms (SNPs) that correlate with OPB-51602 pharmacokinetics and pharmacodynamics</measure>
    <time_frame>1 Year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Analysis</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Advanced solid tumours</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker</intervention_name>
    <description>-</description>
    <arm_group_label>Advanced solid tumours</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll patients from the extension cohort an ongoing phase I study of
        OPB51602, to study the tumour response in selected tumour types, as a proof of concept.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Advanced Solid Tumor

        Exclusion Criteria:

        Non advanced solid tumor
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Yu H, Jove R. The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004 Feb;4(2):97-105. Review.</citation>
    <PMID>14964307</PMID>
  </reference>
  <reference>
    <citation>Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002 Apr;8(4):945-54. Review.</citation>
    <PMID>11948098</PMID>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 27, 2013</lastchanged_date>
  <firstreceived_date>May 23, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
